Immuno-oncology in breast and cervical cancer

Bookmark and Share
Published: 29 Jan 2018
Views: 1709
Prof Neal Ready - Duke University School of Medicine, Durham, USA

Prof Ready speaks with ecancer at the 10th BGICC in Cairo about recent advances with immunotherapy treatments to improve efficacy, reduce toxicity, and widen eligibility.

He outlines the growing number of indications in which checkpoint targeted agents are changing care, and how this may translate to typically non-immunogenic breast tumours.